HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Higher DHA Fatty Acids Linked To Almost 50% Reduction In Alzheimer’s Risk – Framingham Study

Executive Summary

Researchers with 1,490 patients in multigenerational cardiovascular study found subjects with higher levels of DHA omega-3s a lower chance of developing Alzheimer’s.

You may also be interested in...



Optimism About Alzheimer’s Disease: Gene Therapy, Digital Therapeutics And New Biomarkers

Experts in drug development, clinical care and digital therapeutics discuss gaps in the treatment landscape for Alzheimer’s disease, as well as opportunities for prevention and innovation in care delivery.   

NASH: Flying The Plane While Building It

Drug development for nonalcoholic steatohepatitis (NASH), a form of liver disease, is a game of incomplete information: pipeline evolution is occurring in parallel with continued efforts to better understand and manage the disease. To date, no therapy for patients with NASH has been approved and consequences of the condition can be severe, including cirrhosis and hepatocellular carcinoma.

Vitamin D Deficiency Linked To Cardiovascular Risk – Framingham Cohort Study

Moderate to severe vitamin D deficiency is associated with increased cardiovascular risk, according to results of a study of more than 1,700 offspring of participants in the Framingham Heart Study

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152621

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel